Clinical Trials Browser

INDUSTRY × Neoplasms × Imatinib Mesylate × Clear all

Leukemia, Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms

NCT01650805 2014-11-17

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

LymphoidMyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00441155 2013-05-13

Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

Phase 1 Completed

14 enrolled

GastrointestinalSarcoma

Neoplasms, Gastrointestinal Stromal Tumors

NCT01271166 2011-01-06

Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer

Phase 1 Terminated

10 enrolled

Tumor-Agnostic

Neoplasms

Clinical Trials

CARCML

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer